Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials

Luisa Carbognin, Isabella Sperduti, Rolando Nortilli, Matteo Brunelli, Cecilia Vicentini, Francesca Pellini, Giovanni Paolo Pollini, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Paclitaxel and docetaxel represent the most adopted taxanes in the neoadjuvant treatment of HER2-positive breast cancer. Questions still remain with regard to their difference in terms of activity and tolerability.Events for pathological complete response (pCR), severe and febrile neutropenia (FN), and severe neurotoxicity were pooled by adopting a fixed- and random-effect model. A sensitivity analysis to test for the interaction between paclitaxel and docetaxel was accomplished. Absolute differences with 95% confidence intervals (CIs) and the number of patients needed to treat/harm (NNT/NNH) were calculated to derive the Likelihood of being Helped or Harmed (LHH).Data from 15 trials (3601 patients) were included. Paclitaxel significantly increases pCR rate by 6.8% in comparison with docetaxel (43.4%, 95% CI 41.1-45.7% versus 36.6%, 95% CI 34.3-39.0%, p=. 0.0001), regardless of the chemotherapy backbone, with an absolute difference of 9% and 9.2% for anthracycline-based or free-regimens. Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7% (. p=. 0.0012), with no difference if combined with a dual HER2-inhibition. Severe neutropenia and FN are significantly lower with paclitaxel, with an absolute difference of 32.4% (. p

Original languageEnglish
Pages (from-to)262-270
Number of pages9
JournalCancer Treatment Reviews
Volume41
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

docetaxel
Paclitaxel
Breast Neoplasms
Drug Therapy
Febrile Neutropenia
Confidence Intervals
Numbers Needed To Treat
Taxoids
Neoadjuvant Therapy
Anthracyclines
Neutropenia

Keywords

  • Breast cancer
  • Docetaxel
  • HER2-positive
  • Neoadjuvant
  • Paclitaxel
  • Sensitivity analysis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer : Sensitivity analysis of randomized trials. / Carbognin, Luisa; Sperduti, Isabella; Nortilli, Rolando; Brunelli, Matteo; Vicentini, Cecilia; Pellini, Francesca; Pollini, Giovanni Paolo; Giannarelli, Diana; Tortora, Giampaolo; Bria, Emilio.

In: Cancer Treatment Reviews, Vol. 41, No. 3, 01.03.2015, p. 262-270.

Research output: Contribution to journalArticle

Carbognin, Luisa ; Sperduti, Isabella ; Nortilli, Rolando ; Brunelli, Matteo ; Vicentini, Cecilia ; Pellini, Francesca ; Pollini, Giovanni Paolo ; Giannarelli, Diana ; Tortora, Giampaolo ; Bria, Emilio. / Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer : Sensitivity analysis of randomized trials. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 3. pp. 262-270.
@article{3652d061e5624af8bdb6af79b515f857,
title = "Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials",
abstract = "Paclitaxel and docetaxel represent the most adopted taxanes in the neoadjuvant treatment of HER2-positive breast cancer. Questions still remain with regard to their difference in terms of activity and tolerability.Events for pathological complete response (pCR), severe and febrile neutropenia (FN), and severe neurotoxicity were pooled by adopting a fixed- and random-effect model. A sensitivity analysis to test for the interaction between paclitaxel and docetaxel was accomplished. Absolute differences with 95{\%} confidence intervals (CIs) and the number of patients needed to treat/harm (NNT/NNH) were calculated to derive the Likelihood of being Helped or Harmed (LHH).Data from 15 trials (3601 patients) were included. Paclitaxel significantly increases pCR rate by 6.8{\%} in comparison with docetaxel (43.4{\%}, 95{\%} CI 41.1-45.7{\%} versus 36.6{\%}, 95{\%} CI 34.3-39.0{\%}, p=. 0.0001), regardless of the chemotherapy backbone, with an absolute difference of 9{\%} and 9.2{\%} for anthracycline-based or free-regimens. Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7{\%} (. p=. 0.0012), with no difference if combined with a dual HER2-inhibition. Severe neutropenia and FN are significantly lower with paclitaxel, with an absolute difference of 32.4{\%} (. p",
keywords = "Breast cancer, Docetaxel, HER2-positive, Neoadjuvant, Paclitaxel, Sensitivity analysis",
author = "Luisa Carbognin and Isabella Sperduti and Rolando Nortilli and Matteo Brunelli and Cecilia Vicentini and Francesca Pellini and Pollini, {Giovanni Paolo} and Diana Giannarelli and Giampaolo Tortora and Emilio Bria",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ctrv.2015.02.003",
language = "English",
volume = "41",
pages = "262--270",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer

T2 - Sensitivity analysis of randomized trials

AU - Carbognin, Luisa

AU - Sperduti, Isabella

AU - Nortilli, Rolando

AU - Brunelli, Matteo

AU - Vicentini, Cecilia

AU - Pellini, Francesca

AU - Pollini, Giovanni Paolo

AU - Giannarelli, Diana

AU - Tortora, Giampaolo

AU - Bria, Emilio

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Paclitaxel and docetaxel represent the most adopted taxanes in the neoadjuvant treatment of HER2-positive breast cancer. Questions still remain with regard to their difference in terms of activity and tolerability.Events for pathological complete response (pCR), severe and febrile neutropenia (FN), and severe neurotoxicity were pooled by adopting a fixed- and random-effect model. A sensitivity analysis to test for the interaction between paclitaxel and docetaxel was accomplished. Absolute differences with 95% confidence intervals (CIs) and the number of patients needed to treat/harm (NNT/NNH) were calculated to derive the Likelihood of being Helped or Harmed (LHH).Data from 15 trials (3601 patients) were included. Paclitaxel significantly increases pCR rate by 6.8% in comparison with docetaxel (43.4%, 95% CI 41.1-45.7% versus 36.6%, 95% CI 34.3-39.0%, p=. 0.0001), regardless of the chemotherapy backbone, with an absolute difference of 9% and 9.2% for anthracycline-based or free-regimens. Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7% (. p=. 0.0012), with no difference if combined with a dual HER2-inhibition. Severe neutropenia and FN are significantly lower with paclitaxel, with an absolute difference of 32.4% (. p

AB - Paclitaxel and docetaxel represent the most adopted taxanes in the neoadjuvant treatment of HER2-positive breast cancer. Questions still remain with regard to their difference in terms of activity and tolerability.Events for pathological complete response (pCR), severe and febrile neutropenia (FN), and severe neurotoxicity were pooled by adopting a fixed- and random-effect model. A sensitivity analysis to test for the interaction between paclitaxel and docetaxel was accomplished. Absolute differences with 95% confidence intervals (CIs) and the number of patients needed to treat/harm (NNT/NNH) were calculated to derive the Likelihood of being Helped or Harmed (LHH).Data from 15 trials (3601 patients) were included. Paclitaxel significantly increases pCR rate by 6.8% in comparison with docetaxel (43.4%, 95% CI 41.1-45.7% versus 36.6%, 95% CI 34.3-39.0%, p=. 0.0001), regardless of the chemotherapy backbone, with an absolute difference of 9% and 9.2% for anthracycline-based or free-regimens. Paclitaxel significantly improves pCR versus docetaxel with a single HER2-inhibition by 6.7% (. p=. 0.0012), with no difference if combined with a dual HER2-inhibition. Severe neutropenia and FN are significantly lower with paclitaxel, with an absolute difference of 32.4% (. p

KW - Breast cancer

KW - Docetaxel

KW - HER2-positive

KW - Neoadjuvant

KW - Paclitaxel

KW - Sensitivity analysis

UR - http://www.scopus.com/inward/record.url?scp=84923210760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923210760&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.02.003

DO - 10.1016/j.ctrv.2015.02.003

M3 - Article

C2 - 25683304

AN - SCOPUS:84923210760

VL - 41

SP - 262

EP - 270

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -